irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $670KANNUAL SYMPOSIUM FOR NEUROENDOCRINE TUMOR RESEARCH
- #2 $169KOTHER RESEARCH AND EDUCATION PROJECTS
named programs · 3 · from sources
What they call their work
Annual Symposium for Neuroendocrine Tumor Research
Gathers researchers, clinicians, and scientists to present findings and advance knowledge in neuroendocrine tumor disease management
Lifetime Achievement Award
Honors individuals who have made outstanding contributions to neuroendocrine tumor research, clinical practice, and education
Other Research and Education Projects
Supports various initiatives aimed at expanding knowledge and treatment options for neuroendocrine tumors
activities · 8 groups
What they do
-
Patient and Researcher Conferences 2 activities
- Hosts annual and regional educational symposia for medical professionalsOrganizes an annual multidisciplinary symposium on neuroendocrine tumor disease diagnosis, treatment, and management, beginning in 2008, and conducts annual Regional NET Education Conferences in partnership with local cancer centers since 2011. These programs offer CME/MOC/nursing credits and include virtual offerings such as webinars and a podcast series (NETCast).
- Provides accredited medical education programs for healthcare providersOffers continuing medical education through conferences, webinars, and digital content including a monthly eNewsletter, social media messaging, and podcasts to disseminate information about neuroendocrine tumors to healthcare providers across North America.
-
-
Organizational DEI Capacity Building 1 activity
- Advances diversity, equity, and inclusion in the neuroendocrine tumor communityConducts multidisciplinary education, research, and collaboration to advance diversity goals and recognizes members who promote diversity, equity, and inclusion within NANETS and the broader neuroendocrine tumor medical community.
-
-
Academic Research Dissemination 1 activity
- Compiles and publishes annual research abstracts and scientific outputsProduces and disseminates a yearly digital collection of abstracts showcasing current neuroendocrine tumor research and partners with Bioscientifica to publish NANETS research in the journal _Endocrine-Related Cancer_.
-
-
Biomedical Research and Innovation 1 activity
- Conducts and leads clinical and translational research on neuroendocrine tumorsConducts research initiatives in neuroendocrine tumor science, including leading national clinical trials (e.g., through the ALLIANCE for Clinical Trials), identifying molecular prognostic markers, developing gene expression profiling for diagnostic and therapeutic targets, and advancing treatment protocols such as the capecitabine-temozolomide regimen for metastatic cases.
-
-
Cancer Research Funding 1 activity
- Funds research grants for young investigators in neuroendocrine tumor scienceAwards annual research grants to support early-career investigators conducting neuroendocrine tumor research, with 28 recipients funded since 2009.
-
-
Mentorship and Professional Development Programs 1 activity
- Provides mentoring and leadership development for early-career professionalsOffers mentoring, career development, and leadership training opportunities for young medical professionals and trainees through symposium events, workshops, peer networking, committee appointments, and structured mentoring programs.
-
-
Healthcare Professional Recognition Programs 1 activity
- Recognizes excellence in neuroendocrine tumor research, care, and serviceAdministers multiple award categories to honor contributions in clinical care, research, mentorship, diversity, equity and inclusion, and service, including the Lifetime Achievement Award, Distinguished Mentor Award, Outstanding Service Award, and Emerging Leader Award.
-
-
Uncategorized 1 activity
- Develops and publishes clinical practice guidelines for neuroendocrine tumorsLeads the development of consensus guidelines for neuroendocrine tumor (NET) diagnosis, treatment, and management through expert panels and collaborative conferences, publishing manuscripts in peer-reviewed journals. The first consensus guidelines were published in 2010, and updates have addressed high-grade neuroendocrine neoplasms, localized gastric/duodenal/rectal tumors, liver NETs, and palliative care.
-
financials · form 990 · fy2024
revenue
Total revenue$1.21M
Contributions & grants$217K18%
Program service revenue$936K78%
Investment income$52K4%
Other revenue$0
expenses
Total expenses$1.30M
Program expenses89%
Admin / overhead11%
Fundraising0%
Salaries & benefits$0
Grants paid out$0
Largest expense lineProfessional Fees
balance sheet
Total assets$1.47M
Cash$1.10M
Investments$365K
Liabilities$184K
Net assets$1.29M
Liquid reserves13.5 mo
5 years on record · 2020–2024 · YoY revenue +11.0%
leadership · form 990 part vii · fy2024
Who runs it
board members · 14
- ALEXANDRA GANGI — DIRECTOR
- ARVIND DASARI — TREASURER
- CALLISIA CLARKE — SECRETARY
- DANIEL HALPERIN — DIRECTOR
- ERIK MITTRA — DIRECTOR
- JANICE PASIEKA — DIRECTOR
- JENNIFER CHAN — PRESIDENT
- JULIE HALLET — DIRECTOR
- RENUKA IYER — DIRECTOR
- ROBERT RAMIREZ — DIRECTOR
- SIMRON SINGH — VICE PRESIDENT
- TAYMEYAH AL-TOUBAH — DIRECTOR
- THOMAS HOPE — DIRECTOR
- THORVARDUR HALFDANARSON — PRES EMERITA
relationships · 34
Who they work with
- AGA Partner — Engages with AGA as a potential partner organization to support joint initiatives related to neuroendocrine tumors.
- ALLIANCE for Clinical Trials Partner — Collaborates on a national clinical study of a novel treatment for carcinoid tumors.
- Basic/Translational Science Investigator (BTSI) Partner — Collaborates on funding and supporting basic and translational science research in neuroendocrine tumors.
- Bioscientifica Partner — Partner organization for publishing NANETS' research in the journal Endocrine-Related Cancer.
- Bioscientifica Partner — Partners to publish NANETS' research in the journal Endocrine Related Cancer.
- Board of Directors Partner — Ratified the Diversity Statement in October 2020
- Cancer and Leukemia Group B Partner — Collaborates on national clinical trials for pancreatic cancer therapies.
- Dr. Larry Kvols Partner — Co-founded NANETS in 2007.
- Endocrine Related Cancer Partner — Collaborates with the medical journal Endocrine Related Cancer to publish and maximize distribution of clinical guidelines.
- Endocrine Society of Australia Network — Endocrine-Related Cancer is endorsed by the Endocrine Society of Australia, indicating a network affiliation with NANETS.
- European Neuroendocrine Tumor Society Partner — Collaborates through shared advisory board participation and scientific exchange.
- European Society of Endocrinology Network — Endocrine-Related Cancer is endorsed by the European Society of Endocrinology, indicating a network affiliation with NANETS.
- Japanese Hormones and Cancer Society Network — Endocrine-Related Cancer is endorsed by the Japanese Hormones and Cancer Society, indicating a network affiliation with NANETS.
- NANETS Clinical Investigator Scholarship (NCIS) Partner — Partners to fund clinical research initiatives by early-career investigators in neuroendocrine tumors.
- NANETS Theranostics Investigator Grant (NTIG) Partner — Supports research in theranostics for neuroendocrine tumors through dedicated grant funding.
- NANETS Young Investigator (YI) Award Partner — Collaborates to fund and encourage young researchers pursuing specialization in neuroendocrine tumor research.
- NANETS community Network — Network of nearly 600 multidisciplinary medical professionals engaged in research, education, and mentoring in neuroendocrine tumor care.
- National Cancer Institute Government — Engages with NANETS through joint efforts in neuroendocrine tumor research and policy, including membership on the NCI Gastrointestinal Steering Committee and the NCI Neuroendocrine Tumor Task Force.
- National Cancer Institute Government — Funds and collaborates on national clinical trials and research initiatives related to neuroendocrine tumors.
- National Comprehensive Cancer Network Partner — Collaborates through membership on the NET guidelines panel.
- National Comprehensive Cancer Network Partner — Collaborates with NANETS through shared development of clinical guidelines, with NANETS members serving on the NCCN Neuroendocrine Tumor Guidelines panel.
- National Institutes of Health Partner — Jointly hosted the 2022 Multidisciplinary NET Medical Symposium in Washington, DC.
- Neuroendocrine Tumor Research Foundation Network — Endocrine-Related Cancer is endorsed by the Neuroendocrine Tumor Research Foundation, indicating a network affiliation with NANETS.
- Nominating Committee Partner — Internal committee responsible for reviewing nominations and presenting slates for board and officer positions.
- NorCal CarciNET Community Partner — Collaborates with NANETS through joint patient advocacy efforts, with Josh Mailman serving as President and representing patient perspectives on the NANETS Advisory Committee.
- NorCalCarcinet.org Partner — Longtime NANETS member organization whose president was featured in a joint media interview on patient diagnosis and treatment.
- SNMMI Partner — Engages with SNMMI as a potential partner organization to support joint initiatives related to neuroendocrine tumors.
- SSO Partner — Engages with SSO as a potential partner organization to support joint initiatives related to neuroendocrine tumors.
- Society for Endocrinology Network — ERC is an official flagship journal of the Society for Endocrinology, with which NANETS is affiliated through this publication partnership.
- Society of Nuclear Medicine and Molecular Imaging Partner — Collaborates on joint consensus guidelines and co-hosted a one-day program on nuclear medicine technologies for neuroendocrine tumors.
+ 4 more
strategies · 5
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Clinical-Translational Research Modelmethodology: clinical_translational_researchBy integrating clinical trials with biomarker, imaging, and outcomes research, NANETS accelerates the development of targeted therapies because this model bridges patient care and laboratory discovery to produce actionable, evidence-based treatments.
- Consensus-Based Guideline Developmentmethodology: consensus_guideline_developmentBy developing clinical guidelines through expert collaboration and feedback, NANETS standardizes neuroendocrine tumor management because collective validation ensures credibility, consistency, and broad adoption in practice.
- Diversity, Equity, and Inclusion Through Structured Engagementmethodology: diversity_and_inclusion_through_engagementBy recruiting diverse professionals, collecting diversity data, and requiring active engagement, NANETS reduces disparities and strengthens relevance because inclusive participation fosters equitable representation and community-aligned research and care.
- Multidisciplinary Collaboration for Clinical and Research Advancementmethodology: multidisciplinary_collaborationBy integrating professionals across medical specialties and research science, NANETS advances neuroendocrine tumor care because diverse expertise leads to more comprehensive treatment approaches, innovation, and scientific progress.
- Peer-Led, Multidisciplinary Medical Educationmethodology: peer_led_medical_educationBy delivering medical education through peer-led, multidisciplinary networks of NET experts, NANETS accelerates knowledge transfer and improves clinical practice because shared expertise and professional trust enhance engagement and adoption of best practices.